Shenzhen Oralead Pharma

Oralead Pharma is a clinical-stage biotechnology company based in Shenzhen, China, specializing in the oral delivery of macromolecular drugs such as peptides and proteins. The company utilizes a proprietary technology platform designed to overcome the biological barriers of the gastrointestinal tract, enabling the conversion of traditionally injectable biologics into oral dosage forms. Its lead program, ORL-001, is an oral formulation of a GLP-1 receptor agonist currently in clinical development for the treatment of type 2 diabetes and obesity. By focusing on patient-centric delivery methods, Oralead aims to significantly improve treatment adherence and accessibility for chronic metabolic conditions. The company is backed by prominent venture capital firms and continues to expand its pipeline into multi-target metabolic therapies.